Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Study to Assess the Safety and Efficacy of Asacol® (1.2 to 4.8 g/Day) Administered as 400 mg Delayed-release Tablets Given Every 12 Hours for 6 Weeks to Children and Adolescents With Mildly-to-Moderately Active Ulcerative Colitis

NCT00713310 is registered in ClinicalTrials.gov with Warner Chilcott as lead sponsor.

NCT NCT00713310
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00713310 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Study to Assess the Safety and Efficacy of Asacol® (1.2 to 4.8 g/Day) Administered as 400 mg Delayed-release Tablets Given Every 12 Hours for 6 Weeks to Children and Adolescents With Mildly-to-Moderately Active Ulcerative Colitis
Lead sponsor
Warner Chilcott
Phase
Phase 3
Overall status
Completed
Start date
December 31, 2008
Completion date
March 31, 2011
Enrollment
83 (actual)
Sites
42

Conditions

As the registry lists them; a condition with its own page is linked.

ulcerative colitis